PIK3CD and diffuse large B-cell lymphoma: Idelalisib (formerly GS-1101 and CAL-101), a selective oral reversible inhibitor of the p110δ isoform of PI3K, is currently evaluated in an ongoing early phase I study as a single-agent in patients with relapsed/refractory DLBCL.